In MDS, GATA2 is predominant in high risk (i.e., RAEB/RAEB-t) patients, while SAMD9/SAMD9L is inherent on RCC and hypocellular BM [68]. This evidence concerns the gene GATA2 and myelodysplastic syndrome with excess blasts.